Wedbush Maintains Outperform on G1 Therapeutics, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten maintains an Outperform rating on G1 Therapeutics (NASDAQ:GTHX) but lowers the price target from $5 to $4.
February 13, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush maintains an Outperform rating on G1 Therapeutics but lowers the price target from $5 to $4.
While the reduction in price target from $5 to $4 by Wedbush indicates a downward adjustment in valuation expectations, the maintenance of an Outperform rating suggests continued confidence in the company's fundamentals and growth prospects. This mixed signal could lead to short-term price volatility as investors reassess their expectations based on the new price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100